Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Thursday, September 9, 2010

1993 Mitchell TMAU paper : The fish odour syndrome: biochemical, familial, and clinical aspects

This is an interesting TMAU paper from 1993 by a TMAU expert mostly involved in studies that looked at biochemical aspect of TMAU amongst body odor sufferers, Dr Stephen Mitchell of London. Unfortunately he no longer seems to do such research.

Not much seems to have changed since 1993, apart from now they have a test for the genotype testing (DNA test), and also perhaps the 'reference range' in the urine test has come down to a lower level ? In this paper, most of the TMAU cases are regarded positive if their result was around 50% or less. Perhaps today, the borderline is set at around 85% ? The paper seems to have come about due to an article in a UK newspaper in 1991. It resulted in 187 body odor sufferers writing to Dr Mitchell, who then did a survey of them, including a TMAU urine test for 156 of them. Of the 156, 11 were regarded as obvious TMAU cases (using the reference range of the time).

Of the 11 TMAU cases, 6 of them had their parents do the TMAU 'carrier' test (taking 600mg of TMA), which they all 'failed'. Another interesting point is that the 11 cases has TMA levels in the 100's, which seems on the high side.

The fish odour syndrome: biochemical, familial, and clinical aspects.
Ayesh R, Mitchell SC, Zhang A, Smith RL.

Department of Pharmacology and Toxicology, St Mary's Hospital Medical School, (Imperial College), London.
Comment in:

BMJ. 1993 Oct 16;307(6910):1009.
BMJ. 1993 Sep 11;307(6905):639-40.
OBJECTIVES: To study the biochemical, familial, and clinical features of the fish odour syndrome among subjects with suspected body malodour.

DESIGN: Subjects who responded to a newspaper article were screened for the fish odour syndrome by interview and biochemical tests. Families of subjects with the syndrome were tested if possible.

SETTING: St Mary's Hospital, London, and some interviews at subjects' homes.

SUBJECTS: 187 subjects (28 males) with suspected body malodour, of whom 156 (19 males) underwent biochemical tests. Five families of six of the subjects with the fish odour syndrome agreed to further tests.

MAIN OUTCOME MEASURES: Amounts of trimethylamine and trimethylamine N-oxide in urine collected over 24 hours under normal dietary conditions and for eight hours after oral challenge with 600 mg trimethylamine.

RESULTS: The fish odour syndrome was diagnosed in 11 subjects: the percentage of total trimethylamine excreted in their urine samples that was oxidised to trimethylamine N-oxide was < 55% under normal dietary conditions and < 25% after oral challenge with trimethylamine (in normal subjects > 80% of trimethylamine was N-oxidised). Parents of six of the subjects with the syndrome were tested: all showed impaired N-oxidation of excreted trimethylamine (< 80%) after oral challenge, indicating that they were heterozygous carriers of the allele for the syndrome. The syndrome was associated with various psychosocial reactions including clinical depression. CONCLUSIONS: The fish odour syndrome can be inherited in an autosomal recessive fashion. It should be considered as a possible causative factor in patients complaining of body malodour. 
Full paper : The fish odour syndrome: biochemical, familial, and clinical aspects


Post a Comment